Accolade, Inc. (NASDAQ:ACCD) Given Consensus Rating of “Hold” by Analysts

Accolade, Inc. (NASDAQ:ACCD) has earned an average recommendation of “Hold” from the thirteen research firms that are presently covering the stock, MarketBeat.com reports. Twelve analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $6.51.

ACCD has been the topic of a number of recent analyst reports. Stephens restated an “equal weight” rating and set a $7.03 price target on shares of Accolade in a research report on Wednesday, February 12th. William Blair downgraded shares of Accolade from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, January 8th. Leerink Partnrs downgraded shares of Accolade from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, January 8th. Morgan Stanley dropped their price target on shares of Accolade from $6.00 to $5.00 and set an “equal weight” rating on the stock in a research report on Tuesday, December 17th. Finally, Raymond James reaffirmed a “market perform” rating on shares of Accolade in a research note on Thursday, January 9th.

Accolade Trading Up 0.3 %

Shares of NASDAQ:ACCD opened at $6.97 on Thursday. The company has a market cap of $571.49 million, a PE ratio of -3.10 and a beta of 2.18. The company’s 50-day moving average price is $6.28 and its 200 day moving average price is $4.63. Accolade has a fifty-two week low of $3.08 and a fifty-two week high of $10.68. The company has a quick ratio of 2.63, a current ratio of 2.63 and a debt-to-equity ratio of 0.67.

Accolade (NASDAQ:ACCD) last released its quarterly earnings results on Friday, January 10th. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.01. Accolade had a negative net margin of 40.36% and a negative return on equity of 20.74%. Sell-side analysts anticipate that Accolade will post -1.2 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Mission Creek Capital Partners Inc. purchased a new position in shares of Accolade in the third quarter worth approximately $38,000. Pallas Capital Advisors LLC purchased a new position in shares of Accolade in the fourth quarter worth approximately $38,000. Laird Norton Wetherby Trust Company LLC purchased a new position in shares of Accolade in the fourth quarter worth approximately $38,000. Boothbay Fund Management LLC purchased a new position in shares of Accolade in the fourth quarter worth approximately $43,000. Finally, Wolverine Trading LLC purchased a new position in shares of Accolade in the third quarter worth approximately $51,000. 84.99% of the stock is owned by hedge funds and other institutional investors.

Accolade Company Profile

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women’s health specialists, case management specialists, expert medical opinion providers, and primary care physicians.